Y-mAbs Therapeutics, Inc. (YMAB) [Rocket]

In millions, except per share items	Dec-31-21	Dec-31-20	Mar-31-20	Dec-31-19	Mar-31-19	Dec-31-18	Dec-31-17	Dec-31-16
	10-K	10-K	10-Q	10-K	10-Q	10-K	10-K	S-1/A
ASSETS
CURRENT ASSETS
Cash and cash equivalents	181.6	114.6	185.8	207.1	134.2	147.8	90.5
Accounts receivable, net	7.7
Inventories	5.5
Other current assets	7.5	7.7	4.1	4.8	2.8	3.7	0.8
Total current assets	202.3	122.4	189.8	212.0	137.0	151.5	91.4
Property and equipment, net	1.8	1.8	2.0	2.1	0.4	0.2
Operating lease right-of-use assets	3.8	4.6	1.9	2.0	2.3
Intangible assets, net	1.7
Other assets	3.2	3.3	0.4	0.4	0.2	0.2
TOTAL ASSETS	212.8	132.0	194.1	216.4	140.0	151.9	92.1

LIABILITIES AND STOCKHOLDERS' EQUITY
LIABILITIES
Accounts payable	13.6	9.4	10.3	8.5	5.9	5.9	5.9
Accrued liabilities	12.5	8.2	4.0	4.6	3.9	3.3	2.0
Operating lease liabilities, current portion	1.8	2.0	0.5	0.5	0.5
Total current liabilities	27.9	19.5	14.8	13.6	10.3	9.1	7.9
Operating lease liabilities, long-term portion	1.9	2.0	1.5	1.7	2.1
Other liabilities	0.9	2.0	0.5	0.2		0.2
TOTAL LIABILITIES	32.7	26.2	18.7	17.5	14.5	11.4	10.0

Commitments and contingencies (Note 9)
STOCKHOLDERS' EQUITY
Preferred stock, $0.0001 par value, 5,500,000 shares authorized and none issued at June 30, 2023 and December 31, 2022
Common stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Additional paid-in capital	519.2	391.6	367.3	364.7	226.2	225.4	123.9
Accumulated other comprehensive income	1.4	-0.5	0.1	0.1	0.1	0.0	-0.2
Accumulated deficit	-340.5	-285.2	-192.0	-165.9	-100.8	-84.8	-41.6
TOTAL STOCKHOLDERS' EQUITY	180.1	105.8	175.3	198.9	125.5	140.5	82.2
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	212.8	132.0	194.1	216.4	140.0	151.9	92.1